Details of the Drug

General Information of Drug (ID: DMFCF7J)

Drug Name

PLX-200

Indication

Disease Entry	ICD 11	Status	REF
CLN3 Batten disease	5C56	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Cross-matching ID

References

1	ClinicalTrials.gov (NCT04637282) A Randomized. Multicenter, Double-Blind, Placebo-Controlled Safety, Tolerability, and Efficacy Study of PLX-200 in Participants With Mild-to-Moderate Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) Disease. U.S.National Institutes of Health.